Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Novo Nordisk is deeply undervalued, trading at distressed multiples despite a robust pipeline and strong financials. Learn ...

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Novo Nordisk struck a licensing deal valued at up to $2.1 billion to gain access to oral drug-delivery technologies developed by U.S. startup Vivtex, as the Danish drugmaker moves to deepen its ...

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral ...

Vivtex, cofounded by renowned MIT professor Robert Langer, stands to make as much as $2.1 billion if milestones are met.

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures ...

Novo Nordisk (NVO) stock is in focus as the company teams up with Vivtex in a $2.1B deal to develop next-gen oral biologics for obesity and diabetes. Read more here.

Novo Nordisk is slashing the list prices of its flagship weight-loss and diabetes drugs, including Wegovy and Ozempic, by up ...